Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (TWST) is a pioneering company in the field of synthetic biology, specializing in the industrial-scale production of synthetic DNA. At the heart of its operations is a proprietary semiconductor-based DNA synthesis platform, which represents a significant advancement over traditional methods. By synthesizing DNA on a 10,000-well silicon platform instead of conventional 96-well plastic plates, Twist Bioscience achieves unprecedented levels of efficiency, scalability, and cost-effectiveness. This innovation enables the production of high-quality synthetic DNA at a faster pace and lower cost, addressing key inefficiencies in the industry.
The company's product offerings include a wide range of synthetic biology tools such as oligonucleotides, genes, pathways, chassis, and genomes. These tools are critical for applications across multiple industries, including pharmaceutical research, personalized medicine, agriculture, sustainable chemical production, and emerging fields like DNA data storage and in vivo diagnostics. Twist Bioscience's platform not only accelerates research and development but also empowers organizations to innovate in areas such as biodetection and bioengineering.
Operating primarily in the United States, Twist Bioscience serves a diverse customer base that includes biotech firms, pharmaceutical companies, academic institutions, and industrial research organizations. Its business model revolves around direct sales of synthetic DNA products and services, catering to the growing demand for advanced biological engineering solutions. By leveraging its cutting-edge technology, the company has established itself as a critical enabler in the synthetic biology ecosystem.
The broader synthetic biology industry is characterized by rapid innovation and significant growth potential, driven by advancements in genomics, bioinformatics, and sustainable technologies. Twist Bioscience's focus on high-throughput, cost-effective DNA synthesis positions it as a key player in this dynamic market. However, the company faces competition from other DNA synthesis providers, necessitating continuous investment in research and development to maintain its technological edge.
What sets Twist Bioscience apart is its commitment to overcoming traditional limitations in DNA synthesis. By utilizing silicon-based manufacturing, the company not only enhances production efficiency but also expands the possibilities for synthetic biology applications. This unique approach underscores its role as a transformative force in the industry, enabling researchers and organizations to unlock new opportunities in science and technology.
In summary, Twist Bioscience combines technological innovation with a deep understanding of synthetic biology to deliver high-quality DNA synthesis solutions. Its proprietary platform and diverse product offerings make it a vital partner for industries seeking to harness the power of engineered biology. As the demand for synthetic DNA continues to grow, Twist Bioscience remains at the forefront of enabling groundbreaking advancements across multiple sectors.
Twist Bioscience (TWST) has entered a licensing agreement with Abcam (ABCM) for the use of its proprietary VHH phage library, enhancing Abcam's recombinant antibody capabilities. Abcam plans to develop and commercialize antibodies for diagnostics and research, while Twist retains rights for therapeutic applications. This partnership aims to improve industry standards by delivering high-quality reagents and expanding access to challenging antibody targets, with potential commercial benefits for both companies.
Twist Bioscience Corporation (NASDAQ: TWST) has announced a collaboration with Artisan Development Labs Inc. to discover novel antibodies for five undisclosed targets. Twist will utilize its proprietary Library of Libraries, while Artisan will employ its Immune Cell Engineering Foundry to develop custom cell therapeutics. The partnership includes upfront fees, success-based milestones, and royalties on product sales. This collaboration aims to enhance antibody discovery and advance next-generation cell therapies, combining Twist's DNA synthesis platform with Artisan's engineering capabilities.
Twist Bioscience Corporation (NASDAQ: TWST) will announce its financial results for the first quarter of fiscal 2022, ending December 31, 2021, before the market opens on
Twist Bioscience Corporation has announced a breakthrough in DNA synthesis with its new enzymatic synthesis process, offering low-cost, scarless, and scalable technology. The innovation reduces the nucleotide triphosphate (NTP) requirement, significantly cutting costs and enhancing sustainability. Additionally, Twist is partnering with PacBio and Singular Genomics to streamline next-generation sequencing workflows. CEO Emily M. Leproust will present these advancements at the 40th Annual J.P. Morgan Healthcare Conference, aimed at expanding applications in various markets.
Twist Bioscience Corporation (NASDAQ: TWST) has announced the launch of the Twist Alliance Canine Exome Panel, designed for canine genomic research in partnership with the Broad Institute. This panel facilitates next-generation sequencing (NGS) and covers all coding exons of canine genes, including regions relevant to human diseases like cancer. Starting February 2022, the panel aims to enhance comparative studies between human and canine genomics, potentially benefiting both species' health.
Twist Bioscience Corporation (TWST) and Revelar Biotherapeutics announced that their bispecific antibody, RBT-0813, effectively neutralizes the Delta and Omicron variants of SARS-CoV-2 in live virus studies. This innovative antibody, discovered by Twist Biopharma, is progressing in preclinical development with the aim to submit an Investigational New Drug application (IND) in the first half of 2022. The antibody's efficacy was independently confirmed by a team at Yale School of Medicine.
Twist Bioscience Corporation (NASDAQ: TWST) announced that CEO Emily M. Leproust, Ph.D., will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10 at 4:30 p.m. ET. The presentation will be available via a live webcast, accessible through the company’s investor relations page. Following the event, a replay will be archived for 30 days.
Twist is a leader in synthetic biology, utilizing a unique silicon-based platform for DNA synthesis, producing various synthetic DNA products for multiple industries, including healthcare, agriculture, and drug development.
Twist Bioscience Corporation has introduced the Twist 96-Plex Library Prep Kit, designed for next-generation sequencing (NGS), enhancing lab workflows and reducing costs. This innovative kit allows multiplexing of up to 960 samples with reduced hands-on time and reagent usage. The kit has already demonstrated significant results, including identifying genetic associations to canine lung disease, previously missed by microarray technology. Twist aims to optimize genetic research, facilitating advanced studies in genomics and synthetic biology at a lower cost.
Twist Bioscience (TWST) has announced a strategic collaboration with Sosei Heptares to develop therapeutic antibodies targeting G protein-coupled receptors (GPCRs). This partnership combines Twist's synthetic antibody libraries and bioinformatics with Sosei Heptares' StaR® platform. Sosei Heptares will hold exclusive rights to develop and commercialize identified antibody leads. Twist will receive upfront payments, ongoing R&D costs, and milestone payments, though specific financial terms are not disclosed. This alliance aims to expand opportunities in GPCR-targeted antibody therapeutics, addressing a significant area in drug development.
Twist Bioscience Corporation (NASDAQ: TWST) announced the availability of synthetic RNA positive controls for the SARS-CoV-2 Omicron variants, aiding in pandemic response. As of December 6, 2021, Omicron has been confirmed in over 50 countries, prompting the need for effective diagnostics and therapeutic development. CEO Emily M. Leproust emphasized the company's commitment to developing tools to combat COVID-19 variants. Twist also offers a suite of next-generation sequencing tools and is working on controls for the BA.2 variant. The company adheres to strict biosecurity protocols for customer purchases.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
What does Twist Bioscience specialize in?
How does Twist Bioscience's technology differ from traditional DNA synthesis methods?
What industries benefit from Twist Bioscience's products?
How does Twist Bioscience generate revenue?
Who are Twist Bioscience's main competitors?
What makes Twist Bioscience unique in the synthetic biology market?
What applications does Twist Bioscience's technology support?
Where does Twist Bioscience derive most of its revenue?
